title: Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine.
abstract: The respiratory depression induced by buprenorphine and its active metabolite, norbuprenorphine (NBN), was evaluated in rats by measurement of changes in respiratory rate and arterial pCO2 levels. After i.v. bolus administration of buprenorphine no effects were noted over the dose range 0.008 to 3 mg/kg; by contrast, the respiratory rate after rapid i.v. administration of NBN decreased in a dose-dependent fashion within the dose range of 1 to 3 mg/kg, and the arterial pCO2 levels also varied in relation to the change in respiratory rate. The minimum respiratory rate was observed 15 min after NBN administration. Judging by the respiratory depressive effect after i.v. infusion, NBN was approximately 10 times more potent than the parent drug. In spite of the similarity of NBN concentrations in the brain after i.a. and after i.v. administration of NBN (3 mg/kg), neither the respiratory rate nor the arterial pCO2 levels after i.a. administration changed compared with the control levels. Moreover, the NBN concentration in the lungs after i.v. administration was approximately 4-fold higher than that after i.a. administration. NBN-induced depression was rapidly reduced after i.v. administration of naloxone and beta-funaltrexamine, but ICI 174864 was without effect. These results suggest that the respiratory depression induced by NBN may be mediated by opioid mu receptors in the lung rather than in the brain.
authors.affiliation: Department of Pharmacy, University of Tokyo Hospital, Faculty of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Ohtani
authors.forename: H
authors.initials: H
authors.lastname: Kotaki
authors.forename: K
authors.initials: K
authors.lastname: Nishitateno
authors.forename: Y
authors.initials: Y
authors.lastname: Sawada
authors.forename: T
authors.initials: T
authors.lastname: Iga
mesh_terms: D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D002047:Buprenorphine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology*; D002245:Carbon Dioxide / Q000097:blood; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D009270:Naloxone / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D011957:Receptors, Opioid / Q000187:drug effects; D012119:Respiration / Q000187:drug effects*; D012131:Respiratory Insufficiency / Q000139:chemically induced*
chemical_list: D000701:Analgesics, Opioid; D011957:Receptors, Opioid; D002245:Carbon Dioxide; D009270:Naloxone; D002047:Buprenorphine; C043585:norbuprenorphine